La Jolla Pharmaceutical Co. buy melinda
Start price
04.02.18
/
50%
?34.47
Target price
06.08.18
€39.60
Performance (%)
-10.97%
End price
06.08.18
€30.69
Summary
This prediction ended on 06.08.18 with a price of €30.69. The price of La Jolla Pharmaceutical Co. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -10.97%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| La Jolla Pharmaceutical Co. | - | - | - | - |
| iShares Core DAX® | -2.526% | -5.194% | 4.911% | 51.996% |
| iShares Nasdaq 100 | -0.032% | 1.561% | 21.789% | 95.664% |
| iShares Nikkei 225® | -4.202% | -7.550% | 31.128% | 52.994% |
| iShares S&P 500 | -0.802% | 0.160% | 15.782% | 66.529% |
Comments by melinda for this prediction
In the thread La Jolla Pharmaceutical Co. diskutieren
Biotechnologie und medizinische SecteurRecherche
La Jolla Pharmaceutical Co
Décion LJPC FDA-501 oder zur Behandlung von Hypotension bei Erwachsenen mit distributiven Schock oder vasodilatateurLJPC-501 (Angiotensin II) (NES)
2018.02.28
Die FDA genehmigte Giapreza, früher bekannt als die LJPC-501, 21. Dezember 2017 bekannt
(Laufzeit überschritten)
Stopped prediction by melinda for La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?16.08
25.10.18
25.10.18
€31.57
30.10.19
30.10.19
0.00%
30.10.19
30.10.19
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?27.15
22.12.17
22.12.17
€72.16
29.12.17
29.12.17
7.84%
29.12.17
29.12.17
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?29.10
29.08.17
29.08.17
€72.16
29.08.17
29.08.17
7.19%
29.08.17
29.08.17
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?22.65
12.04.17
12.04.17
€28.86
21.04.17
21.04.17
11.91%
21.04.17
21.04.17